thiotepa

RxCUI 10473 ingredient

Contraindicated with · 24

Diagnoses8

Neutropenia Agranulocytosis Leukopenia Thrombocytopenia Cytopenia Pregnancy Reproduction Drug Hypersensitivity

Condition families16

Leukocyte Disorders Bone Marrow Diseases Blood Platelet Disorders Liver Diseases Kidney Diseases Hematologic Diseases Reproductive Physiological Phenomena Hemic and Lymphatic Diseases Urologic Diseases Male Urogenital Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Digestive System Diseases Urogenital Diseases Drug-Related Side Effects and Adverse Reactions Chemically-Induced Disorders

Indicated for · 36

Diagnoses8

Sarcoma Neoplasms, Connective and Soft Tissue Genital Neoplasms, Female Adenocarcinoma Lymphoma Carcinoma Neoplasms, Glandular and Epithelial Genital Diseases, Female

Condition families28

Urinary Bladder Neoplasms Ovarian Neoplasms Urologic Neoplasms Ovarian Diseases Adnexal Diseases Urinary Bladder Diseases Endocrine Gland Neoplasms Gonadal Disorders Breast Neoplasms Breast Diseases Lymphatic Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Urogenital Neoplasms Neoplasms by Histologic Type Genital Diseases Endocrine System Diseases Neoplasms by Site Hemic and Lymphatic Diseases Urologic Diseases Neoplasms Male Urogenital Diseases Female Urogenital Diseases Skin Diseases Female Urogenital Diseases and Pregnancy Complications Skin and Connective Tissue Diseases Urogenital Diseases Immune System Diseases

MED-RT, published by the VA through NLM. Relationships attach at the ingredient level, not to a specific product or dose.

RADV audits Coding jobs Chart counter Hours & decimal time About Contact Help Terms Privacy

Innova Coding Suite extension — both tools in your browser: Add to Chrome · Add to Edge

InnovaRx — Innova Health Strategies. ICD-10-CM and the CMS-HCC risk adjustment models are published by CMS and NCHS and are in the public domain. Effective date 2026-10-22 travels in the URL, so this link shows anyone exactly what you see.